In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

(AP Photo/Eugene Hoshiko, File)(Eugene Hoshiko / AP) Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by slow adoption of its respiratory syncytial virus (RSV) shot and weak demand ...

Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...